Phase I-II Study of Association of Deferasirox, Vitamin D and Azacytidine as Treatment of High Risk MDS (IPSS Int-2 and High)

Trial Profile

Phase I-II Study of Association of Deferasirox, Vitamin D and Azacytidine as Treatment of High Risk MDS (IPSS Int-2 and High)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 18 Jul 2017

At a glance

  • Drugs Deferasirox (Primary) ; Azacitidine; Colecalciferol
  • Indications Myelodysplastic syndromes
  • Focus Adverse reactions
  • Most Recent Events

    • 11 Jul 2017 Planned End Date changed from 1 Feb 2018 to 1 Feb 2019.
    • 11 Jul 2017 Planned primary completion date changed from 1 Feb 2017 to 1 Feb 2019.
    • 27 Oct 2015 Planned End Date changed from 1 Nov 2015 to 1 Feb 2018 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top